PIK3CA and cancer: The following study of Lehmann et al[10] revealed that PIK3CA kinase domain mutations were frequent in the LAR subtype, and the combination of AR antagonism and PI3K inhibition could synergistically inhibit LAR TNBC cell growth.[12] This study exemplifies the importance of integrating different types of genomic data into exploration of discovery of cancer treatment targets.